BackProPhase Labs Overview

ProPhase Labs Other Liabilities

ProPhase Labs's other liabilities is $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

ProPhase Labs Other Liabilities History

Loading

ProPhase Labs vs. peers: Other Liabilities Comparison

Loading

ProPhase Labs Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ProPhase Labs (PRPH) FAQ

ProPhase Labs (PRPH) currently reports a other liabilities of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore ProPhase Labs's other liabilities history and peer comparisons.

ProPhase Labs's other liabilities changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ProPhase Labs reported $0 in other liabilities as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ProPhase Labs, and consider following PRPH for alerts when major investors trade the stock.

ProPhase Labs is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRPH with unrelated industries.